Feature

The paints and coatings company looks especially resilient in a tough housing market. It’s set to outshine competitors.

Stocks that aren’t sensitive to economic ups and downs are a smart way to protect your portfolio.

This week’s blockbuster IPO of Circle, a leading issuer of stablecoins, shows how crypto is increasingly going mainstream. Here’s how to invest.

“Tesla without Musk would be a disaster for Tesla shareholders,” a longtime Tesla bull told Barron’s.

U.S. drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be worth up to $25 billion.

Investors should pay attention to where the government is spending our tax dollars, but that doesn’t mean chasing returns based on political movements.

Investment advisors weigh in with the market moves they are making in the trade-war era.

Global diversification is working this year and could continue to do so for years to come.

Causeway’s Sarah Ketterer likes AstraZeneca and Gucci’s parent company, Kering. Where else she’s picking up bargains.

The networking equipment manufacturer has quickly gone from a company to avoid to a Wall Street darling. There’s more room ahead for gains.

A joint venture between U.S. industrial company GE Vernova and Japanese conglomerate Hitachi is making gains.

The White House’s “rescissions” package is headed for Congress. It included $9.4 billion in reductions, from public media and foreign aid.

GOP senators have changes they want to make to the House version. Medicaid and SALT are in the crosshairs.

It once seemed like the perfect investment—offering better returns than stocks with less risk. Lately, though, private equity has become an albatross.

Government staffing cuts aren’t a good reason to claim early. What to know so you don’t shortchange your retirement.

Not all dividend stocks are equal in this type of economic environment.

The cruise operator’s stock recently took a hit after cautious management earnings commentary and investor jitters, but it’s well positioned to correct course.

If you sold this May, you missed a historic surge.

Stocks seemed to have moved past tariffs worries. A lot could still go wrong.

Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for drugmakers.

the decision throws cold water on some GOP lawmakers’ contention that levies on imports will fill the gaping deficit left by the tax bill moving through Congress.

Atlas Energy Solutions is a heavily shorted stock.

After years of U.S. stock-market gains, investment experts see more value abroad. One recommendation: 15% to 20% in foreign markets.

The Make America Healthy Again movement cites soda as one reason for bad diets. The big beverage companies aren’t going down without a fight.

Investors appear to be forgetting that the full impact of even reduced tariffs has yet to be felt.